AWHLOTCIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Aspira Women's Health Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.22−0.01 (-2.61%)
Close on Oct 19, 2026
- Market cap
- $9.91M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.2859 (−56.07%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Aspira Women's Health Inc. reported revenue of $170.00K for the twelve months to Jun 30, 2026. Free cash flow was -$7.05M.
Revenue
$170.00K
TTM Q2 2026
Operating income
-$6.90M
TTM Q2 2026
Free cash flow
-$7.05M
FY2025
EPS, diluted
-$0.31
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $9.91M
- P/E ratio
- –
- Price to sales
- 58.31
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -71.08%
Fundamentals
- Revenue
- $170.00K
- Net income
- -$10.01M
- EPS, diluted
- -$0.31
- Free cash flow
- -$7.05M
- Book value per share
- -$0.16
- Diluted shares
- 44M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$170.00K
Gross profit
$5.02M-15.4% YoY
Operating income
-$6.90M
Net income
-$10.01M
EPS, diluted
-$0.31
Free cash flow
–
Reported periodTrailing twelve months